- March 2013 – the U.S Food and Drug Administration (FDA) approved Johnson & Johnson’s Invokana®, the first sodium-glucose cotransporter 2 (SGLT2) inhibitors approved to treat type 2 diabetes in the country.
- January 2015 – Invokana® becomes one of the fastest growing prescription drugs with sales of over $200 million worldwide.
- May 2015 – Institute for Safe Medication Practices (ISMP)’s warns the FDA of adverse reactions linked to the drug, reporting 450 serious adverse event reports. The FDA issues a drug safety communication for Invokana®, warning users that the medication could result in ketoacidosis.
- December 2015 –The FDA issues a new warning for SGLT2 inhibitors, such as Invokana®, about the risk of dangerous acid levels in the blood (ketoacidosis) as well as urinary tract infections.
- February 2016 – The European Medicines Agency (EMA) issues new warnings for SGLT2 diabetes drugs like Invokana, advising patients of diabetic ketoacidosis risks. FDA records also show 506 Adverse Event reports related to ketoacidosis and 310 reports related to kidney injury from patients taking Invokana®.
- July 2016 – Diabetologia study finds an increased death rate with multiple hospital admissions for ketoacidosis.
We Can Help
If you or a loved one developed complications after taking Invokana®, you may be entitled to financial compensation. Recovery may include compensation for your medical bills, pain and suffering, lost wages, and loss of spousal consortium. Avram Blair & Associates P.C. is headquartered in Houston, Texas but handles Invokana® cases nationwide. To find out if you have a claim, please call Avram Blair & Associates P.C. at (800) 428-2603 or contact us online for your free consultation.